This business information is not released now.

This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.

AnGes, Inc.
Pharmaceutical/Drug Discovery

last update:2021/9/1

Delegates :
President & CEO, Ei Yamada

Incorporated :
December  17 , 1999

Paid in Capital :
33359 Million yen  

Employees :
121 人

Address :
Saito Bio-Incubator 7-7-15, Saito-asagi, Ibaraki OSAKA



Attachment :

Mission/Background :
AnGes , Inc. is a biopharmaceutical company with the mission of providing patients suffering from diseases for which no effective therapy has been available to date, with innovative drugs. AnGes focuses on the development of gene-based medicines, a next-generation biopharmaceutical.

Technology & Business
AnGes , Inc. was founded in December 1999 based on an innovative discovery by researchers at Osaka University. AnGes has already undergone the first stage of research and development, and is now in the second stage of realizing clinical application. For our lead product, HGF Plasmid (gene therapy) for the treatment of Chronic arterial occlusive disease, the company got the conditional and time-limited approval in March 2019. And its practicalizing started in September 2019 in Japan. This is the world’s first commercialization using the Plasmid DNA method. Development of NF-κB decoy oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases including, low back pain, and DNA vaccines for high blood pressure is also under way. Furthermore, AnGes started co-development of the DNA vaccine with Osaka University from March 2020 for COVID-19.
Products & Service
Products & Service Name
HGF Plasmid
Target: Critical Limb Ischemia
Conditional approval in 2019. For Approval by 2024 PMS is on progress
COVID-19 DNA Vaccine
Target: COVID-19
Conducting P3 in Japan
NF-kB Decoy Oligonucleotide
Target: Chronic Discogenic Low Back Pain
Start P2 study in the US
COVID-19 Treatment
Target: COVID-19
Conduct P2a study
Hypertension DNA Vaccine
Target: Hypertension
Plan next clinical trial
-HGF Plasmid for Critical Limb Ischemia: Conditional approval in 2019. PMS on going for approval by 2024
-COVID-19 Vaccine and Treatment: Clinical Trial on going
-NF-kB Decoy Oligonucleotide for Chronic Discogenic Low Back Pain: Clinical Trail on going

Hot news

Alliance strategy
License-out: HGF Plasmid (excluding Critical Limb Ischemia in the US and Japan), NF-kB Decoy Oligonucleotide, and Hypertension DNA Vaccine

Inquiry form:

This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.